Spiro, who had most recently served as president of Specialty Generics business at Mallinckrodt Pharmaceuticals and the president of US Injectables at Hikma, will be responsible for the overall strategy, implementation and growth of Lupin's US generics business, the company said in a regulatory filing.from Industry-Economic Times
Read The Rest:economictimes...
